Journal of Immunology Research

Immunoregulation in Multiple Sclerosis: Pathogenesis and Therapeutic Implications


Publishing date
21 Mar 2014
Status
Closed
Submission deadline
01 Nov 2013

1Department of Clinical Immunology, Hospital Clínico San Carlos, Madrid, Spain

2Inserm/Université U 1013, Hôpital Necker - Enfants Malades, Paris, France

3Department of Immunology, Germans Trias i Pujol University Hospital, Barcelona, Spain

This issue is now closed for submissions.
More articles will be published in the near future.

Immunoregulation in Multiple Sclerosis: Pathogenesis and Therapeutic Implications

This issue is now closed for submissions.
More articles will be published in the near future.

Description

After trauma, multiple sclerosis (MS) represents the most common cause of neurological disability in young people, with a significant personal, social, and economic public health burden. MS is a chronic inflammatory demyelinating disease of the central nervous system, in which repeated episodes of autoimmune-mediated demyelination result in the formation of gliotic scar tissue plaques associated with varying degrees of axonal loss. Moreover, a defective immunoregulation has been demonstrated at different levels in MS, defect that can be partially restored by some therapies used for MS. A better knowledge of the interplaying factors that modulate the activation and/or function of immune cells will contribute to better understanding of the etiopathogenesis of MS and will enable the design of therapeutical strategies for individualized cell therapy. Potential topics include, but are not limited to:

  • Recent advances in immunopathogenesis of MS
  • Advances on immune targets for MS
  • Sex dimorphism and immunoregulation
  • Role of microbiota in MS
  • Vitamin D as an immunomodulator for MS
  • Immunoregulatory effects of MS therapies
  • Recent developments of therapies based on immunopathophysiology
  • Towards a personalized therapy for MS

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/jir/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/jir/imspt/ according to the following timetable:

Journal of Immunology Research
 Journal metrics
Acceptance rate40%
Submission to final decision91 days
Acceptance to publication32 days
CiteScore3.330
Impact Factor3.404
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.